Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Kamikawa Runs for LDP Presidency, Resolved to Empower Healthcare Realm
September 12, 2024
- Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
September 12, 2024
- Antivirals Push Up Japan’s Drug Spending in FY2023: MHLW
September 12, 2024
- Ex-Minister Kato Joins Fray in LDP Race, Pledges Inflation-Linked Drug Prices
September 11, 2024
- MHLW Proposes Periodic Survey of Vaccine Prices in Japan
September 11, 2024
- Takaichi Vows to Bolster Japan’s Self-Sufficiency of Drugs, Vaccines in LDP Race
September 11, 2024
- Japan Extends Re-Examination Period for Entyvio, Zintus
September 11, 2024
- AMED Research Exploring Low-Cost Method to Analyze Nitrosamine Impurities
September 11, 2024
- First Drug Delisting in Simplified Process Slated for March-End 2026: MHLW
September 10, 2024
- Eisai COO Calls for LDP Collaboration in AD Diagnosis, Treatment
September 10, 2024
- MHLW to Accept English Dossiers from Foreign Makers
September 9, 2024
- MHLW Proposes Scope of Observational Research Subject to Clinical Trials Act
September 9, 2024
- MHLW Floats 3 Perspectives to Codify Rules for Drug Supply Management
September 9, 2024
- PMDA-Led Inspections Will Help Straighten Up Generic Makers: MHLW Councilor
September 6, 2024
- MOF Intent on Expanding Scope of Off-Year Revision in 2025: Budget Examiner
September 6, 2024
- Trodelvy Up for Japan Panel Review on Sept. 12, Meiji COVID Jab on Agenda Too
September 6, 2024
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
- Japan Poised to Launch FIH Trial System in FY2029 to Attract Global Seeds
September 5, 2024
- Japan Healthcare Spend Hit Record High of 47 Trillion Yen in FY2023
September 4, 2024
- Japan’s HIV and AIDS Cases Up for First Time in 7 Years
September 4, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…